Impact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types

Area of Science:

• Oncology
• Cancer Metastasis
• Pharmacological Interventions

Background:

• Bone metastasis is a significant predictor of poor prognosis in cancer patients.
• Bone-modifying agents (BMA) are standard for managing skeletal-related events (SREs).
• The impact of BMA on overall survival post-bone metastasis remains incompletely understood.

Purpose of the Study:

• To investigate the association between BMA treatment and survival duration in patients with bone metastasis.
• To identify factors influencing survival outcomes in patients with metastatic bone disease.

Main Methods:

• Retrospective analysis of 539 cancer patients with bone metastasis.
• Statistical analysis including log-rank tests and Cox proportional hazards models.
• Identification of independent prognostic factors for post-bone metastasis survival.

Main Results:

• Median survival varied significantly by cancer type, with thyroid, breast, prostate, and kidney cancers showing longer survival than GI, head and neck, and urinary tract cancers.
• In non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) mutation status significantly impacted survival (mutation+ vs. mutation-).
• Treatment with BMA was a significant positive prognostic factor, increasing median survival from 7.8 to 21.9 months (p < 0.001).
• BMA demonstrated a survival benefit particularly in poor-prognosis cancers like GI cancer and EGFR-negative NSCLC.

Conclusions:

• BMA treatment is associated with improved post-bone metastasis survival.
• BMA should be considered not only for SRE management but also for potentially enhancing survival.
• The survival benefits of BMA are particularly notable in specific cancer types with historically poor outcomes, such as GI cancer and NSCLC without EGFR mutations.